Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Lantheus Medical Imaging signs Mo-99 supply contract deal with Institute for Radioelements

Lantheus Medical Imaging : 21 March, 2013  (Company News)
Lantheus Medical Imaging agrees a new supply contract with the Institute for Radioelements (IRE) to receive a supply of molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m), for use in its TechneLite (Technetium Tc 99m Generator) generators.


Under the terms of the five-year agreement, IRE will provide an increasing supply of Mo-99 through December 31, 2017, which will further strengthen Lantheus' global Mo-99 supply chain strategy designed to make the Company less vulnerable to supply shortages. The new agreement also provides for the transition to Mo-99 sourced from Low-Enriched Uranium (LEU) targets during the period of the agreement upon IRE's completion of its ongoing conversion programme to modify its facilities and processes in accordance with Belgian nuclear security commitments.



"Our agreement with IRE further demonstrates our ongoing efforts and commitment to maximizing global access to Mo-99,” said Jeff Bailey, President and Chief Executive Officer, Lantheus Medical Imaging. "We are focused on enhancing our balanced and diverse supply chain for this important medical isotope to ensure that we consistently meet the needs of customers and their patients. Over the course of this agreement, IRE will also help support our strategic initiatives related to supply chain stability and the conversion to 100 percent LEU-derived Mo-99."



As a leader in the radiopharmaceutical business, Lantheus has developed a world class, globally diversified and balanced Mo-99 supply chain for the procurement of Mo-99. The Company receives Mo-99 from four of the five major processors and seven of the eight associated reactors. Additionally, Lantheus actively supports the US Government initiative to encourage the use of LEU in the manufacture of medical isotopes. Lantheus recently added the LEU TechneLite generator to its portfolio of nuclear medicine products.


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo